Effects of psychopharmacological treatment with antidepressants on the vascular system

Vascular Pharmacology

Volumn 96-98, Issue , 2017, Pages 11-18

  Kahl, Kai G ^a,b   Westhoff Bleck, Mechthild ^a   Krüger, Tillmann H C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Working Group on Polypharmacy   (Germany)

Author keywords

Antidepressants; Antipsychotics; Cardiovascular effects; Diabetes; Morbidity; Mortality; QTc prolongation; Vascular system; Weight gain

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SYSTEMATIC REVIEW; ANIMAL; CLASSIFICATION; CLINICAL DECISION MAKING; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR SYSTEM; CLINICAL DECISION-MAKING; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS;

EID: 85027226032     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2017.07.004     Document Type: Review

References (191)

1. Babigian, H.M., Odoroff, C.L., The mortality experience of a population with psychiatric illness. Am. J. Psychiatry 126:4 (1969), 470–480.
2. Harris, E.C., Barraclough, B., Excess mortality of mental disorder. Br. J. Psychiatry 173 (1998), 11–53.
3. Ivbijaro, G., Excess mortality in severe mental disorder: the need for an integrated approach. World Psychiatry 16:1 (2017), 48–49.
4. Lawrence, D., Excess mortality, mental illness and global burden of disease. Epidemiol. Psychiatr. Sci. 24:2 (2015), 141–143.
5. Liu, N.H., Daumit, G.L., Dua, T., Aquila, R., Charlson, F., Cuijpers, P., Druss, B., Dudek, K., Freeman, M., Fujii, C., Gaebel, W., Hegerl, U., Levav, I., Munk Laursen, T., Ma, H., Maj, M., Elena Medina-Mora, M., Nordentoft, M., Prabhakaran, D., Pratt, K., Prince, M., Rangaswamy, T., Shiers, D., Susser, E., Thornicroft, G., Wahlbeck, K., Fekadu Wassie, A., Whiteford, H., Saxena, S., Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 16:1 (2017), 30–40.
6. Lumme, S., Pirkola, S., Manderbacka, K., Keskimaki, I., Excess mortality in patients with severe mental disorders in 1996–2010 in Finland. PLoS One, 11(3), 2016, e0152223.
7. Miller, C., Bauer, M.S., Excess mortality in bipolar disorders. Curr. Psychiatry Rep., 16(11), 2014, 499.
8. Nordentoft, M., Wahlbeck, K., Hallgren, J., Westman, J., Osby, U., Alinaghizadeh, H., Gissler, M., Laursen, T.M., Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One, 8(1), 2013, e55176.
9. Pratt, L.A., Druss, B.G., Manderscheid, R.W., Walker, E.R., Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey. Gen. Hosp. Psychiatry 39 (2016), 39–45.
10. Saha, S., Chant, D., McGrath, J., A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 64:10 (2007), 1123–1131.
11. Tidemalm, D., Waern, M., Stefansson, C.G., Elofsson, S., Runeson, B., Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12,103 individuals with and without contact with psychiatric services. Clin. Pract. Epidemiol. Ment. Health, 4, 2008, 23.
12. Walker, E.R., McGee, R.E., Druss, B.G., Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 72:4 (2015), 334–341.
13. Malzberg, B., Life tables for patients with mental disease. J. Am. Stat. Assoc. 27:177 (1932), 160–174.
14. Chesney, E., Goodwin, G.M., Fazel, S., Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13:2 (2014), 153–160.
15. Fekadu, A., Medhin, G., Kebede, D., Alem, A., Cleare, A.J., Prince, M., Hanlon, C., Shibre, T., Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. Br. J. Psychiatry 206:4 (2015), 289–296.
16. Ho, C., Jin, A., Nyunt, M.S., Feng, L., Ng, T.P., Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults. Postgrad. Med. 128:7 (2016), 642–647.
17. Laursen, T.M., Nordentoft, M., Mortensen, P.B., Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 10 (2014), 425–448.
18. Olfson, M., Gerhard, T., Huang, C., Crystal, S., Stroup, T.S., Premature mortality among adults with schizophrenia in the United States. JAMA Psychiat. 72:12 (2015), 1172–1181.
19. Wahlbeck, K., Westman, J., Nordentoft, M., Gissler, M., Laursen, T.M., Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br. J. Psychiatry 199:6 (2011), 453–458.
20. Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., Penninx, B.W., Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both. Br. J. Psychiatry 202:1 (2013), 22–27.
21. Newcomer, J.W., Hennekens, C.H., Severe mental illness and risk of cardiovascular disease. JAMA 298:15 (2007), 1794–1796.
22. Brown, S., Kim, M., Mitchell, C., Inskip, H., Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 196:2 (2010), 116–121.
23. Osby, U., Westman, J., Hallgren, J., Gissler, M., Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur. J. Pub. Health 26:5 (2016), 867–871.
24. Vigo, D., Thornicroft, G., Atun, R., Estimating the true global burden of mental illness. Lancet Psychiatry 3:2 (2016), 171–178.
25. Colton, C.W., Manderscheid, R.W., Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis., 3(2), 2006, A42.
26. Kritharides, L., Chow, V., Lambert, T.J., Cardiovascular disease in patients with schizophrenia. Med. J. Aust. 206:2 (2017), 91–95.
27. Lawrence, D., Hancock, K.J., Kisely, S., The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ, 346, 2013, f2539.
28. Laursen, T.M., Munk-Olsen, T., Nordentoft, M., Mortensen, P.B., Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry 68:6 (2007), 899–907.
29. Roshanaei-Moghaddam, B., Katon, W., Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr. Serv. 60:2 (2009), 147–156.
30. Lambert, T.J., Velakoulis, D., Pantelis, C., Medical comorbidity in schizophrenia. Med. J. Aust. 178:Suppl (2003), S67–70.
31. Davidson, S., Judd, F., Jolley, D., Hocking, B., Thompson, S., Hyland, B., Cardiovascular risk factors for people with mental illness. Aust. N. Z. J. Psychiatry 35:2 (2001), 196–202.
32. McCreadie, R.G., Scottish Schizophrenia Lifestyle G, Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br. J. Psychiatry 183 (2003), 534–539.
33. Lang, U.E., Borgwardt, S., Molecular mechanisms of depression: perspectives on new treatment strategies. Cell. Physiol. Biochem. 31:6 (2013), 761–777.
34. Chaddha, A., Robinson, E.A., Kline-Rogers, E., Alexandris-Souphis, T., Rubenfire, M., Mental health and cardiovascular disease. Am. J. Med. 129:11 (2016), 1145–1148.
35. Lichtman, J.H., Froelicher, E.S., Blumenthal, J.A., Carney, R.M., Doering, L.V., Frasure-Smith, N., Freedland, K.E., Jaffe, A.S., Leifheit-Limson, E.C., Sheps, D.S., Vaccarino, V., Wulsin, L., American Heart Association Statistics Committee of the Council on E, Prevention, the Council on C, Stroke N, Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 129:12 (2014), 1350–1369.
36. Stringhini, S., Carmeli, C., Jokela, M., Avendaño, M., Muennig, P., Guida, F., Ricceri, F., d'Errico, A., Barros, H., Bochud, M., Chadeau-Hyam, M., Clavel-Chapelon, F., Costa, G., Delpierre, C., Fraga, S., Goldberg, M., Giles, G.G., Krogh, V., Kelly-Irving, M., Layte, R., Lasserre, A.M., Marmot, M.G., Preisig, M., Shipley, M.J., Vollenweider, P., Zins, M., Kawachi, I., Steptoe, A., Mackenbach, J.P., Vineis, P., Kivimäki, M., Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 17 million men and women. Lancet 389:10075 (2017), 1229–1237.
37. Andreassen, O.A., Djurovic, S., Thompson, W.K., Schork, A.J., Kendler, K.S., O'Donovan, M.C., Rujescu, D., Werge, T., van de Bunt, M., Morris, A.P., McCarthy, M.I., International Consortium for Blood Pressure G, Diabetes Genetics R, Meta-analysis C, Psychiatric Genomics Consortium Schizophrenia Working G, Roddey, J.C., LK, McEvoy, Desikan, R.S., Dale, A.M., Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am. J. Hum. Genet. 92:2 (2013), 197–209.
38. Laursen, T.M., Nordentoft, M., Heart disease treatment and mortality in schizophrenia and bipolar disorder - changes in the Danish population between 1994 and 2006. J. Psychiatr. Res. 45:1 (2011), 29–35.
39. Lawrence, D., Kisely, S., Inequalities in healthcare provision for people with severe mental illness. J. Psychopharmacol. 24:4 Suppl (2010), 61–68.
40. Cunningham, C., Peters, K., Mannix, J., Physical health inequities in people with severe mental illness: identifying initiatives for practice change. Issues Ment. Health Nurs. 34:12 (2013), 855–862.
41. Correll, C.U., Detraux, J., De Lepeleire, J., De Hert, M., Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14:2 (2015), 119–136.
42. Albrecht, J., Muller-Oerlinghausen, B., Cardiovascular side effects of lithium. Dtsch. Med. Wochenschr. 105:18 (1980), 651–655.
43. Astrup, T., Rasmussen, J., Is there an enhancing effect of neuroleptic drugs on blood coagulation and thrombosis. Thromb. Diath. Haemorrh. 13 (1965), 418–427.
44. Axelsson, S., Hagg, S., Eriksson, A.C., Lindahl, T.L., Whiss, P.A., In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 34:8 (2007), 775–780.
45. Blankfield, R.P., Blood pressure, fluid retention and the cardiovascular risk of drugs. Futur. Cardiol. 8:4 (2012), 489–493.
46. Akoudad, S., Aarts, N., Noordam, R., Ikram, M.A., Tiemeier, H., Hofman, A., Stricker, B.H., Vernooij, M.W., Visser, L.E., Antidepressant use is associated with an increased risk of developing microbleeds. Stroke 47:1 (2016), 251–254.
47. 2 +-activated contractions of rabbit isolated aorta. Gen. Pharmacol. 17:5 (1986), 607–610.
48. Gothe, F., Enache, D., Wahlund, L.O., Winblad, B., Crisby, M., Lokk, J., Aarsland, D., Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment. Panminerva Med. 54:3 (2012), 161–170.
49. Grool, A.M., van der Graaf, Y., Vincken, K.L., Witkamp, T.D., Mali, W.P., Geerlings, M.I., Antidepressant use is related to larger white matter lesion volume in patients with symptomatic atherosclerotic disease: the SMART-MR study. J. Neurol. 260:1 (2013), 197–206.
50. Lippi, G., Montagnana, M., Favaloro, E.J., Franchini, M., Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin. Thromb. Hemost. 35:3 (2009), 325–336.
51. Bushnell, C., Depression and the risk of stroke in women: an identification and treatment paradox. Stroke 42:10 (2011), 2718–2719.
52. Clarke, D.M., Currie, K.C., Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med. J. Aust. 190:7 Suppl (2009), S54–60.
53. Davidson, K.W., Korin, M.R., Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve. Clin. J. Med. 77:Suppl. 3 (2010), S20–26.
54. Ghoge, H., Sharma, S., Sonawalla, S., Parikh, R., Cerebrovascular diseases and depression. Curr. Psychiatry Rep. 5:3 (2003), 231–238.
55. Hare, D.L., Toukhsati, S.R., Johansson, P., Jaarsma, T., Depression and cardiovascular disease: a clinical review. Eur. Heart J. 35:21 (2014), 1365–1372.
56. Li, C.T., Bai, Y.M., Tu, P.C., Lee, Y.C., Huang, Y.L., Chen, T.J., Chang, W.H., Su, T.P., Major depressive disorder and stroke risks: a 9-year follow-up population-based, matched cohort study. PLoS One, 7(10), 2012, e46818.
57. Moretti, R., Bernobich, E., Esposito, F., Torre, P., Antonello, R.M., De Angelis, L., Bellini, G., Depression in vascular pathologies: the neurologist's point of view. Vasc. Health Risk Manag. 7 (2011), 433–443.
58. Coupland, C., Hill, T., Morriss, R., Moore, M., Arthur, A., Hippisley-Cox, J., Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ, 352, 2016, i1350.
59. Bachmann, C.J., Aagaard, L., Burcu, M., Glaeske, G., Kalverdijk, L.J., Petersen, I., Schuiling-Veninga, C.C., Wijlaars, L., Zito, J.M., Hoffmann, F., Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. Eur. Neuropsychopharmacol. 26:3 (2016), 411–419.
60. Mars, B., Heron, J., Kessler, D., Davies, N.M., Martin, R.M., Thomas, K.H., Gunnell, D., Influences on antidepressant prescribing trends in the UK: 1995–2011. Soc. Psychiatry Psychiatr. Epidemiol. 52:2 (2017), 193–200.
61. Pratt, L.A., Brody, D.J., Gu, Q., Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief 76 (2011), 1–8.
62. Beach, S.R., Celano, C.M., Noseworthy, P.A., Januzzi, J.L., Huffman, J.C., QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54:1 (2013), 1–13.
63. Beach, S.R., Kostis, W.J., Celano, C.M., Januzzi, J.L., Ruskin, J.N., Noseworthy, P.A., Huffman, J.C., Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry 75:5 (2014), e441–449.
64. Bouffard, Y., Palmier, B., Bouletreau, P., Motin, J., Acute tricyclic antidepressant intoxication. Evaluation of severity and treatment. A study of 16 patients with cardiovascular manifestations (author's transl). Ann. Med. Interne 133:4 (1982), 256–260.
65. Funai, Y., Funao, T., Ikenaga, K., Takahashi, R., Hase, I., Nishikawa, K., Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval. Osaka City Med. J. 60:1 (2014), 11–19.
66. Golacka, E., Intoxication with tricyclic antidepressants in 2000: regional toxicological poison data from the center in Lublin. Przegl. Lek. 60:4 (2003), 289–291.
67. Hasnain, M., Vieweg, W.V., QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 28:10 (2014), 887–920.
68. Jasiak, N.M., Bostwick, J.R., Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann. Pharmacother. 48:12 (2014), 1620–1628.
69. Maljuric, N.M., Noordam, R., Aarts, N., Niemeijer, M.N., van den Berg, M.E., Hofman, A., Kors, J.A., Stricker, B.H., Visser, L.E., Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam study. Br. J. Clin. Pharmacol. 80:4 (2015), 698–705.
70. Mitsumori, Y., Nakamura, Y., Hoshiai, K., Nagayama, Y., Adachi-Akahane, S., Koizumi, S., Matsumoto, M., Sugiyama, A., In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. Cardiovasc. Toxicol. 10:4 (2010), 275–282.
71. Pacher, P., Kecskemeti, V., Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr. Pharm. Des. 10:20 (2004), 2463–2475.
72. Sala, M., Coppa, F., Cappucciati, C., Brambilla, P., d'Allio, G., Caverzasi, E., Barale, F., De Ferrari, G.M., Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr. Opin. Investig. Drugs 7:3 (2006), 256–263.
73. Spindelegger, C.J., Papageorgiou, K., Grohmann, R., Engel, R., Greil, W., Konstantinidis, A., Agelink, M.W., Bleich, S., Ruether, E., Toto, S., Kasper, S., Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int. J. Neuropsychopharmacol., 18(4), 2014.
74. Thanacoody, H.K., Thomas, S.H., Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol. Rev. 24:3 (2005), 205–214.
75. Tisdale, J.E., Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can. Pharm. J. 149:3 (2016), 139–152.
76. Uchida, M., Spencer, A.E., Biederman, J., Castro, V.M., Kenworthy, T., Chan, J., Rosales, A.M., Newton-Cheh, C., Perlis, R.H., A systematic evaluation of the QTc interval and antidepressants in youth: an electronic health record study. J. Dev. Behav. Pediatr. 36:6 (2015), 434–439.
77. Wenzel-Seifert, K., Wittmann, M., Haen, E., QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 108:41 (2011), 687–693.
78. Delini-Stula, A., Baier, D., Kohnen, R., Laux, G., Philipp, M., Scholz, H.J., Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor–results of the drug utilization observation studies. Pharmacopsychiatry 32:2 (1999), 61–67.
79. Georgotas, A., McCue, R.E., Friedman, E., Cooper, T.B., A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. J. Clin. Psychopharmacol. 7:6 (1987), 413–416.
80. Johnson, E.M., Whyte, E., Mulsant, B.H., Pollock, B.G., Weber, E., Begley, A.E., Reynolds, C.F., Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry 14:9 (2006), 796–802.
81. Kiev, A., Masco, H.L., Wenger, T.L., Johnston, J.A., Batey, S.R., Holloman, L.C., The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann. Clin. Psychiatry 6:2 (1994), 107–115.
82. Laird, L.K., Lydiard, R.B., Morton, W.A., Steele, T.E., Kellner, C., Thompson, N.M., Ballenger, J.C., Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J. Clin. Psychiatry 54:6 (1993), 224–228.
83. Leinonen, E., Lepola, U., Koponen, H., Mehtonen, O.P., Rimon, R., Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr. Scand. 96:6 (1997), 497–504.
84. Neshkes, R.E., Gerner, R., Jarvik, L.F., Mintz, J., Joseph, J., Linde, S., Aldrich, J., Conolly, M.E., Rosen, R., Hill, M., Orthostatic effect of imipramine and doxepin in depressed geriatric outpatients. J. Clin. Psychopharmacol. 5:2 (1985), 102–106.
85. Ottevanger, E.A., Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. L'Encéphale 21:4 (1995), 317–321.
86. Roberts, R.L., Joyce, P.R., Mulder, R.T., Begg, E.J., Kennedy, M.A., A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2:3 (2002), 191–196.
87. Tricyclic antidepressants. N. Engl. J. Med., 300(9), 1979, 504–506.
88. Hoc, J., The clinical efficacy and side-effects of mianserin and nortriptyline in depressed out-patients: a double-blind randomized trial. Curr. Med. Res. Opin. 8:4 (1982), 282–289.
89. Schneider, L.S., Cooper, T.B., Severson, J.A., Zemplenyi, T., Sloane, R.B., Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J. Clin. Psychopharmacol. 8:6 (1988), 402–408.
90. Veith, R.C., Raskind, M.A., Caldwell, J.H., Barnes, R.F., Gumbrecht, G., Ritchie, J.L., Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N. Engl. J. Med. 306:16 (1982), 954–959.
91. Castro, V.M., Clements, C.C., Murphy, S.N., Gainer, V.S., Fava, M., Weilburg, J.B., Erb, J.L., Churchill, S.E., Kohane, I.S., Iosifescu, D.V., Smoller, J.W., Perlis, R.H., QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ, 346, 2013, f288.
92. Coupland, C.A., Dhiman, P., Barton, G., Morriss, R., Arthur, A., Sach, T., Hippisley-Cox, J., A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol. Assess. 15:28 (2011), 1–202 (iii–iv).
93. Glassman, A.H., Cardiovascular effects of antidepressant drugs: updated. Int. Clin. Psychopharmacol. 13:Suppl. 5 (1998), S25–30.
94. Andrade, C., Sandarsh, S., Chethan, K.B., Nagesh, K.S., Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J. Clin. Psychiatry 71:12 (2010), 1565–1575.
95. Cheng, Y.L., Hu, H.Y., Lin, X.H., Luo, J.C., Peng, Y.L., Hou, M.C., Lin, H.C., Lee, F.Y., Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore), 94(46), 2015, e2022.
96. Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., Hippisley-Cox, J., Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 343, 2011, d4551.
97. Quinn, G.R., Singer, D.E., Chang, Y., Go, A.S., Borowsky, L.H., Udaltsova, N., Fang, M.C., Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am. J. Cardiol. 114:4 (2014), 583–586.
98. Morriss, R., Antidepressants are associated with hospital admitted intracranial bleeds in people taking other medication associated with bleeding. Evid. Based Ment. Health, 19(1), 2016, 24.
99. Shin, J.Y., Park, M.J., Lee, S.H., Choi, S.H., Kim, M.H., Choi, N.K., Lee, J., Park, B.J., Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ, 351, 2015, h3517.
100. Salvi, V., Mencacci, C., Barone-Adesi, F., H1-histamine receptor affinity predicts weight gain with antidepressants. Eur. Neuropsychopharmacol. 26:10 (2016), 1673–1677.
101. Andersohn, F., Schade, R., Suissa, S., Garbe, E., Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 166:5 (2009), 591–598.
102. Pan, A., Sun, Q., Okereke, O.I., Rexrode, K.M., Rubin, R.R., Lucas, M., Willett, W.C., Manson, J.E., Hu, F.B., Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 55:1 (2012), 63–72.
103. Ratliff, S., Mezuk, B., Depressive symptoms, psychiatric medication use, and risk of type 2 diabetes: results from the health and retirement study. Gen. Hosp. Psychiatry 37:5 (2015), 420–426.
104. Barnard, K., Peveler, R.C., Holt, R.I., Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 36:10 (2013), 3337–3345.
105. Kammer, J.R., Hosler, A.S., Leckman-Westin, E., DiRienzo, G., Osborn, C.Y., The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS). J. Diabetes Complicat. 30:2 (2016), 242–247.
106. Da Silva, M.A., Dugravot, A., Balkau, B., Roussel, R., Fumeron, F., Elbaz, A., Canonico, M., Singh-Manoux, A., Nabi, H., Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, beta-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. Int. J. Epidemiol. 44:6 (2015), 1927–1940.
107. Kivimaki, M., Batty, G.D., Jokela, M., Ebmeier, K.P., Vahtera, J., Virtanen, M., Brunner, E.J., Tabak, A.G., Witte, D.R., Kumari, M., Singh-Manoux, A., Hamer, M., Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association?. Biol. Psychiatry 70:10 (2011), 978–984.
108. Thase, M.E., Larsen, K.G., Reines, E., Kennedy, S.H., The cardiovascular safety profile of escitalopram. Eur. Neuropsychopharmacol. 23:11 (2013), 1391–1400.
109. Taylor, C.B., Youngblood, M.E., Catellier, D., Veith, R.C., Carney, R.M., Burg, M.M., Kaufmann, P.G., Shuster, J., Mellman, T., Blumenthal, J.A., Krishnan, R., Jaffe, A.S., Investigators, E., Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch. Gen. Psychiatry 62:7 (2005), 792–798.
110. Zuidersma, M., Conradi, H.J., van Melle, J.P., Ormel, J., de Jonge, P., Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J. Psychosom. Res. 74:1 (2013), 25–30.
111. Wozniak, G., Toska, A., Saridi, M., Mouzas, O., Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med. Sci. Monit. 17:9 (2011), RA205–214.
112. Haritos, V.S., Ghabrial, H., Ahokas, J.T., Ching, M.S., Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 10:7 (2000), 591–603.
113. Crone, C.C., Gabriel, G.M., Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 43:6 (2004), 361–394.
114. Qirjazi, E., McArthur, E., Nash, D.M., Dixon, S.N., Weir, M.A., Vasudev, A., Jandoc, R., Gula, L.J., Oliver, M.J., Wald, R., Garg, A.X., Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS One, 11(8), 2016, e0160768.
115. FDA. Drug safety communication: revised recommendations for Celexa (Citalopram Hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012, MedWatch.
116. FDA. Drug safety communication: abnormal heart rhythms associated with high doses of Celexa (Citalopram Hydrobromide). 2012.
117. Tseng, Y.L., Chiang, M.L., Huang, T.F., Su, K.P., Lane, H.Y., Lai, Y.C., A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb. Res. 126:6 (2010), 517–523.
118. van Zyl, L.T., Lesperance, F., Frasure-Smith, N., Malinin, A.I., Atar, D., Laliberte, M.A., Serebruany, V.L., Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J. Thromb. Thrombolysis 27:1 (2009), 48–56.
119. Lam, R.W., Antidepressants and QTc prolongation. J. Psychiatry Neurosci. 38:2 (2013), E5–6.
120. Kharofa, J., Sekar, P., Haverbusch, M., Moomaw, C., Flaherty, M., Kissela, B., Broderick, J., Woo, D., Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 38:11 (2007), 3049–3051.
121. Yekehtaz, H., Farokhnia, M., Akhondzadeh, S., Cardiovascular considerations in antidepressant therapy: an evidence-based review. J. Tehran Heart Cent. 8:4 (2013), 169–176.
122. Parissis, J.T., Fountoulaki, K., Filippatos, G., Adamopoulos, S., Paraskevaidis, I., Kremastinos, D., Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications. Int. J. Cardiol. 116:2 (2007), 153–160.
123. Pizzi, C., Rutjes, A.W., Costa, G.M., Fontana, F., Mezzetti, A., Manzoli, L., Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am. J. Cardiol. 107:7 (2011), 972–979.
124. Lekakis, J., Ikonomidis, I., Papoutsi, Z., Moutsatsou, P., Nikolaou, M., Parissis, J., Kremastinos, D.T., Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int. J. Cardiol. 139:2 (2010), 150–158.
125. Nezafati, M.H., Vojdanparast, M., Nezafati, P., Antidepressants and cardiovascular adverse events: a narrative review. ARYA Atheroscler. 11:5 (2015), 295–304.
126. Nezafati, M.H., Eshraghi, A., Vojdanparast, M., Abtahi, S., Nezafati, P., Selective serotonin reuptake inhibitors and cardiovascular events: a systematic review. J. Res. Med. Sci., 21, 2016, 66.
127. Carceller-Sindreu, M., de Diego-Adelino, J., Portella, M.J., Garcia-Moll, X., Figueras, M., Fernandez-Vidal, A., Queralto, J.M., Puigdemont, D., Alvarez, E., Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur. Arch. Psychiatry Clin. Neurosci., 2017, 10.1007/s00406-016-0758-6 [Epub ahead of print].
128. Hanash, J.A., Hansen, B.H., Hansen, J.F., Nielsen, O.W., Rasmussen, A., Birket-Smith, M., Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. J. Cardiovasc. Pharmacol. 60:4 (2012), 397–405.
129. 2 + sensitivity. Br. J. Pharmacol. 127:3 (1999), 740–746.
130. 2 +]i. J. Cardiovasc. Pharmacol. 35:6 (2000), 849–854.
131. Baumann, P., Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31:6 (1996), 444–469.
132. Kim, J., Phongsamran, P., Park, S., Use of antidepressant drugs in transplant recipients. Prog. Transplant. 14:2 (2004), 98–104.
133. Westenberg, H.G., Sandner, C., Tolerability and safety of fluvoxamine and other antidepressants. Int. J. Clin. Pract. 60:4 (2006), 482–491.
134. Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., Skaar, T.C., Muller, D.J., Gaedigk, A., Stingl, J.C., Clinical Pharmacogenetics Implementation C, Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93:5 (2013), 402–408.
135. Nevels, R.M., Gontkovsky, S.T., Williams, B.E., Paroxetine-the antidepressant from hell? Probably not, but caution required. Psychopharmacol. Bull. 46:1 (2016), 77–104.
136. Yeragani, V.K., Pesce, V., Jayaraman, A., Roose, S., Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol. Psychiatry 52:5 (2002), 418–429.
137. Serebruany, V.L., Suckow, R.F., Cooper, T.B., O'Connor, C.M., Malinin, A.I., Krishnan, K.R., van Zyl, L.T., Lekht, V., Glassman, A.H., Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am. J. Psychiatry 162:6 (2005), 1165–1170.
138. Kostev, K., Rex, J., Eith, T., Heilmaier, C., Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. Ger. Med. Sci., 12, 2014, Doc15.
139. Funk, K.A., Bostwick, J.R., A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 47:10 (2013), 1330–1341.
140. Bak, S., Tsiropoulos, I., Kjaersgaard, J.O., Andersen, M., Mellerup, E., Hallas, J., Garcia Rodriguez, L.A., Christensen, K., Gaist, D., Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 33:6 (2002), 1465–1473.
141. Yuan, H.W., Wang, C.X., Zhang, N., Bai, Y., Shi, Y.Z., Zhou, Y., Wang, Y.L., Zhang, T., Zhou, J., Yu, X., Sun, X.Y., Liu, Z.R., Zhao, X.Q., Wang, Y.J., Poststroke depression and risk of recurrent stroke at 1 year in a Chinese cohort study. PLoS One, 7(10), 2012, e46906.
142. Douglas, I., Smeeth, L., Irvine, D., The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br. J. Clin. Pharmacol. 71:1 (2011), 116–120.
143. Shin, D., Oh, Y.H., Eom, C.S., Park, S.M., Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J. Neurol. 261:4 (2014), 686–695.
144. Alvares, G.A., Quintana, D.S., Hickie, I.B., Guastella, A.J., Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J. Psychiatry Neurosci. 41:2 (2016), 89–104.
145. Ho, J.M., Gomes, T., Straus, S.E., Austin, P.C., Mamdani, M., Juurlink, D.N., Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J. Clin. Psychiatry 75:6 (2014), e552–558.
146. Diaper, A., Rich, A.S., Wilson, S.J., Craig, K., Dourish, C.T., Dawson, G.R., Nutt, D.J., Bailey, J.E., Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum. Psychopharmacol. 28:6 (2013), 562–575.
147. Taylor, D., Lenox-Smith, A., Bradley, A., A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther. Adv. Psychopharmacol. 3:3 (2013), 151–161.
148. Howell, C., Wilson, A.D., Waring, W.S., Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br. J. Clin. Pharmacol. 64:2 (2007), 192–197.
149. Kok, R., Nolen, W., Heeren, T., Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry, 15(8), 2007, 725 (author reply 726).
150. Mbaya, P., Alam, F., Ashim, S., Bennett, D., Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum. Psychopharmacol. 22:3 (2007), 129–133.
151. Taylor, D., Venlafaxine and cardiovascular toxicity. BMJ, 340, 2010, c411.
152. Wernicke, J.F., Prakash, A., Kajdasz, D.K., Houston, J., Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J. Diabetes Complicat. 23:5 (2009), 349–359.
153. Wise, T.N., Wiltse, C.G., Iosifescu, D.V., Sheridan, M., Xu, J.Y., Raskin, J., The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int. J. Clin. Pract. 61:8 (2007), 1283–1293.
154. Xue, F., Strombom, I., Turnbull, B., Zhu, S., Seeger, J., Treatment with duloxetine in adults and the incidence of cardiovascular events. J. Clin. Psychopharmacol. 32:1 (2012), 23–30.
155. Vuppalanchi, R., Hayashi, P.H., Chalasani, N., Fontana, R.J., Bonkovsky, H., Saxena, R., Kleiner, D., Hoofnagle, J.H., Drug-Induced Liver Injury N, Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment. Pharmacol. Ther. 32:9 (2010), 1174–1183.
156. Lee, W.M., Drug-induced hepatotoxicity. N. Engl. J. Med. 349:5 (2003), 474–485.
157. Deardorff, W.J., Grossberg, G.T., The pharmacology and clinical use of the antidepressants vilazodone, levomilnacipran, and vortioxetine for depression in the elderly. Curr. Geriatr. Rep. 4:4 (2015), 301–311.
158. Asnis, G.M., Henderson, M.A., Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr. Dis. Treat. 11 (2015), 125–135.
159. Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W.M., Liebowitz, M., Khan, A., Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J. Psychiatry Neurosci. 39:1 (2014), 40–49.
160. Blum, S.I., Tourkodimitris, S., Ruth, A., Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. J. Affect. Disord. 170 (2015), 230–236.
161. Bruno, A., Morabito, P., Spina, E., Muscatello, M.R., The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr. Neuropharmacol. 14:2 (2016), 191–199.
162. Citrome, L., Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int. J. Clin. Pract. 69:2 (2015), 151–155.
163. Gommoll, C.P., Greenberg, W.M., Chen, C., A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder. J. Drug Assess. 3:1 (2014), 10–19.
164. Mago, R., Forero, G., Greenberg, W.M., Gommoll, C., Chen, C., Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin. Drug Investig. 33:10 (2013), 761–771.
165. Montgomery, S.A., Gommoll, C.P., Chen, C., Greenberg, W.M., Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 20:2 (2015), 148–156.
166. Roman, M.W., Wilkinson, S.M., Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary. Issues Ment. Health Nurs. 35:12 (2014), 972–974.
167. Sambunaris, A., Bose, A., Gommoll, C.P., Chen, C., Greenberg, W.M., Sheehan, D.V., A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J. Clin. Psychopharmacol. 34:1 (2014), 47–56.
168. Scott, L.J., Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. CNS Drugs 28:11 (2014), 1071–1082.
169. Shiovitz, T., Greenberg, W.M., Chen, C., Forero, G., Gommoll, C.P., A randomized, double-blind, placebo-controlled trial of the efficacy and safety of Levomilnacipran ER 40–120 mg/day for prevention of relapse in patients with major depressive disorder. Innov. Clin. Neurosci. 11:1–2 (2014), 10–22.
170. Zaman, S., McLaughlin, M.R., Levomilnacipran (Fetzima) for major depressive disorder. Am. Fam. Physician 92:8 (2015), 727–731.
171. Annapandian, V.M., John, G.T., Mathew, B.S., Fleming, D.H., Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation 88:9 (2009), 1143–1145.
172. Terhardt, J., Lederbogen, F., Feuerhack, A., Hamann-Weber, B., Gilles, M., Schilling, C., Lecei, O., Deuschle, M., Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin. Neuropharmacol. 36:6 (2013), 198–202.
173. Lee, Y.C., Lin, C.H., Lin, M.S., Lin, J.W., Chang, C.H., Lai, M.S., Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J. Clin. Psychopharmacol. 33:6 (2013), 782–789.
174. Olesen, O.V., Linnet, K., Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 55:5 (1997), 235–243.
175. Mease, P.J., Zimetbaum, P.J., Duh, M.S., Vekeman, F., Guerin, A., Boerstoel-Streefland, M., Jiang, W., Lefebvre, P., Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French Health Data. Ann. Pharmacother. 45:2 (2011), 179–188.
176. Robinson, D.S., Nies, A., Corcella, J., Cooper, T.B., Spencer, C., Keefover, R., Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients. J. Clin. Psychiatry 43:5 Pt 2 (1982), 8–15.
177. Kiyan, S., Aksay, E., Yanturali, S., Atilla, R., Ersel, M., Acute myocardial infarction associated with amitriptyline overdose. Basic Clin. Pharmacol. Toxicol. 98:5 (2006), 462–466.
178. Cohen, H.W., Gibson, G., Alderman, M.H., Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am. J. Med. 108:1 (2000), 2–8.
179. Katsi, V.K., Marketou, M., Vamvakou, G., Makris, T., Tousoulis, D., Stefanadis, C.I., Vardas, P., Kallikazaros, I.E., Novel antidepressant drugs, arterial hypertension and cardiovascular disease. Recent Pat. Cardiovasc. Drug Discov. 8:3 (2013), 178–185.
180. Waslick, B., Cardiac effects of desipramine. J. Am. Acad. Child Adolesc. Psychiatry 34:2 (1995), 125–126.
181. Waslick, B.D., Walsh, B.T., Greenhill, L.L., Giardina, E.G., Sloan, R.P., Bigger, J.T., Bilich, K., Cardiovascular effects of desipramine in children and adults during exercise testing. J. Am. Acad. Child Adolesc. Psychiatry 38:2 (1999), 179–186.
182. Biederman, J., Thisted, R.A., Greenhill, L.L., Ryan, N.D., Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J. Clin. Psychiatry 56:3 (1995), 87–93.
183. Raskind, M., Veith, R., Barnes, R., Gumbrecht, G., Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am. J. Psychiatry 139:9 (1982), 1114–1117.
184. Roose, S.P., Glassman, A.H., Giardina, E.G., Johnson, L.L., Walsh, B.T., Bigger, J.T. Jr., Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J. Clin. Psychopharmacol. 7:4 (1987), 247–251.
185. Tulen, J.H., Bruijn, J.A., de Man, K.J., Pepplinkhuizen, L., van den Meiracker, A.H., Manin't Veld, A.J., Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (org 3770). J. Clin. Psychopharmacol. 16:2 (1996), 135–145.
186. Lee, S., Lee, H.A., Kim, S.J., Kim, K.S., Cellular mechanisms for trazodone-induced cardiotoxicity. Hum. Exp. Toxicol. 35:5 (2016), 501–510.
187. Service, J.A., Waring, W.S., QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin. Toxicol. (Phila.) 46:1 (2008), 71–73.
188. van Melle, J.P., de Jonge, P., Honig, A., Schene, A.H., Kuyper, A.M., Crijns, H.J., Schins, A., Tulner, D., van den Berg, M.P., Ormel, J., Investigators, M.-I., Effects of antidepressant treatment following myocardial infarction. Br. J. Psychiatry 190 (2007), 460–466.
189. de Jonge, P., Honig, A., van Melle, J.P., Schene, A.H., Kuyper, A.M., Tulner, D., Schins, A., Ormel, J., Investigators, M.-I., Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am. J. Psychiatry 164:9 (2007), 1371–1378.
190. Mago, R., Tripathi, N., Andrade, C., Cardiovascular adverse effects of newer antidepressants. Expert. Rev. Neurother. 14:5 (2014), 539–551.
191. Yeh, T.C., Kao, L.C., Tzeng, N.S., Kuo, T.B., Huang, S.Y., Chang, C.C., Chang, H.A., Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: findings from the Taiwan Study of Depression and Anxiety (TAISDA). Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016), 60–67.